Dr. Stuart Lutzker is the President of Research & Development of ArriVent Biopharma. Dr. Lutzker has extensive drug development experience, having served as Vice President and Head of Oncology, Early Clinical Development at Genentech from 2009-2021. At Genentech, he led the early development of multiple now-approved oncology drugs including Kadcyla, Polivy, Venclexta, Cotellic and Tecentriq. Previously, Dr. Lutzker was a medical oncologist and cancer researcher at the NCI Designated-Cancer Institute of New Jersey, where he split time between patient care and laboratory-based cancer research. He obtained a joint M.D./Ph.D. in Biochemistry from Columbia University College of Physicians and Surgeons. Following his residency and fellowship in Internal Medicine and Medical Oncology at Yale-New Haven Hospital, Dr. Lutzker completed post-doctoral research training in the Department of Molecular Biology at Princeton University. Dr. Lutzker has also served as faculty for the AACR/ASCO Methods in Clinical Cancer Research Workshop in Vail, CO.